Status | Study |
Active, not recruiting |
Study Name: RA-2 13-cis Retinoic Acid (Isotretinoin) Condition: Male Infertility Klinefelter's Syndrome Y-chromosome Micro Date: 2014-02-10 Interventions: Drug: 13-cis retinoic acid Acc |
Completed |
Study Name: Mitochondrial Dysfunction in Phelan-McDermid Syndrome: Explaining Clinical Variation and Providing a Path Towards Treatment Condition: Phelan-McDermid Syndrome Date: 2013-11-25 |
Completed |
Study Name: Prenatal Screening for Down Syndrome With DNAFirst Condition: Trisomy 21 Trisomy 18 Trisomy 13 Date: 2013-10-17 |
Recruiting |
Study Name: Dendritic Cells Plus Autologous Tumor RNA in Uveal Melanoma Condition: Uveal Melanoma Date: 2013-09-17 Interventions: Biological: Autologous Dendritic Cells loaded with autologous Tumor RNA |
Recruiting |
Study Name: Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive Genotype Condition: Acute Myeloid Leukemia Date: 2012-02-13 Interventions: Drug: sorafenib, vorinostat and bortezomib Escalating dose cohorts of sorafenib, vorinostat and bortezom |
Completed |
Study Name: Clinical Trial in 22q13 Deletion Syndrome(Phelan-McDermid Syndrome) Condition: 22q13 Deletion Syndrome Phelan-McDermid Syndrome Date: 2012-02-01 Interventions: Drug: Insulin-Like Growth Factor-1 (IGF-1) |
Completed |
Study Name: Study of the Pathophysiological Mechanisms Involved in Bleeding Events Condition: Oculocerebrorenal Syndrome Date: 2011-03-11 Interventions: Other: Blood sample Blood sample |
Terminated |
Study Name: LENA-LMA-5:Lenalidomide in Acute Myeloid Leukemia (AML) Condition: AML Date: 2010-07-29 Interventions: Drug: Lenalidomide Initial dose of oral lenalidomide is 10 |
Completed |
Study Name: A Study of Withdrawal of Immunosuppression and Donor Lymphocyte Infusions Following Allogeneic Transplant for Pediatric Hematologic Malignancies Condition: Acute Leukemia Acute Myeloid Leukemia Acute Lymphoblastic Date: 2009-12-17 Interventions: Other: Withdrawal of immunosuppression and donor lymphocyte infusion Intervention will involve fast with |
Terminated |
Study Name: Combination of 5-azacitidine and Lenalidomide in Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) Myelodysplastic Syndromes Condition: Myelodysplastic Syndromes Acute Myelogenous Leukemia Date: 2009-06-17 Interventions: Drug: Azacitidine 75 mg/m² |